Transcript for Earnings call for the Financials Results for the quarter ended June 30, 2026

August 07, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejebhoy Towers “Exchange Plaza” Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai – 400051 Scrip Code (BSE): 544009 Symbol: BLUEJET Sub: Transcript of the Earnings Call with Analysts/Investors on Financial Results for the quarter ended June 30, 2026 Dear Sir / Ma'am, Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed the transcript of the Earnings Call with the Analysts/ Investors on the Financial Results for the quarter ended June 30, 2026 held on August 03, 2026. The same is also available at: https://bluejethealthcare.com/investor-presentation/ You are requested to take the same on record. Thanking you, Yours faithfully, For Blue Jet Healthcare Limited Sweta Poddar Company Secretary & Compliance Officer (M. No.: F12287) “Blue Jet Healthcare Limited Q1 FY27 Earnings Conference Call” August 03, 2026 MANAGEMENT: MR. SHIVEN ARORA – MANAGING DIRECTOR MR. V.K. SINGH – CHIEF OPERATING OFFICER MR. GANESH KARUPPANNAN – CHIEF FINANCIAL OFFICER MR. SANJAY SINHA – DEPUTY CHIEF FINANCIAL OFFICER MODERATOR: MR. ADVAIT BHADEKAR – ERNST & YOUNG Page 1 of 16 Blue Jet Healthcare Limited August 03, 2026 Moderator: Ladies and gentlemen good day and welcome to the Blue Jet Healthcare Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Advait from EY. Thank you. Over to you, sir. Advait: Thank you, Shruthi. Good evening, and warm welcome, everyone, to Q1 FY27 Earnings Call of Blue Jet Healthcare Limited. Please note the investor presentation and the financial results are available on the company's website and the stock exchanges. Also anything said on this call, which reflects our outlook for the future or which should be construed as a forward-looking statement must be reviewed in conjunction with the risks that the company face. The conference call is being recorded under transfer along with audio of the team will be made available on the company website, as well as on the Exchanges. Please also note that the audio of the conference call is the corporate material of Blue Jet Healthcare Limited and cannot be copied, rebroadcasted or attributed in press or media without a written consent of the company. From the management, we have with us Mr. Shiven Arora, Managing Director; Mr. V.K. Singh, Chief Operating Officer; Mr. Ganesh Karuppannan, Chief Financial Officer and Mr. Sanjay Sinha, Deputy Chief Financial Officer. Now I request Mr. Shiven Arora; Managing Director of Blue Jet Healthcare Limited to provide you with the updates for the quarter ended 30th June 2026. Thank you and over to you, sir. Shiven Arora: Thank you, Advait. Good evening, everyone and thank you for joining us today. The first quarter of FY27 marks an encouraging start to the financial year and reflects improving business momentum across our core businesses. Over the past 2 years, we have remained focused on strengthening Blue Jet's manufacturing capabilities, expanding our R&D infrastructure and deepening our customer partnerships. FY26 was a year of building the foundation for the next phase of growth, and we are pleased to see the early benefits of these investments beginning to reflect in our operating performance. During the quarter, we reported revenue from operations of INR293 crores and an EBITDA of INR98 crores, reflecting healthy sequential improvement. Ganesh will take you through the financial performance in greater detail. The improvement during this quarter was primarily supported by stronger performance in our PI vertical, following the normalization of our customer inventory while the contrast media and high-intensity sweetener businesses continue to provide stability and diversification to our portfolio. Alongside the improvement in business performance, we continue to make meaningful progress on our long-term strategic initiatives. Execution activities at our Vizag project have commenced with key statutory approvals in place, engineering activity is progressing as planned. Page 2 of 16 Blue Jet Healthcare Limited August 03, 2026 Our Hyderabad R&D center also remains on-track and is expected to become operational during the current month. Further strengthening our ability to support customer development and expand our chemistry capabilities. At Unit 3, backward integration project continues to progress well and remains on-track with commercial contribution expected during the second half of FY27. The successful completion of our QIP, marks an important milestone in Blue Jet's growth journey. It not only strengthens our balance sheet, but also provides us with the financial flexibility to accelerate the execution of our long-term strategy. Our vision for Vizag, extends well beyond capacity expansion. We are building a future-ready manufacturing and innovation platform that will significantly expand our capabilities across GMP intermediates, complex APIs and CDMO manufacturing. The facility is being designed with flexibility to support multiple chemistry platforms, including high potency manufacturing capabilities, enabling us to participate in a broader range of innovator-led development and commercial programs. Together with our Hyderabad R&D Center, Vizag will create an integrated platform from process development and scale up through to commercial manufacturing allowing us to strengthen our partnerships with global pharmaceutical and biotechnology companies. Our long- term ambition is to establish Blue Jet as a globally recognized partner in complex chemistry combining scientific innovation, manufacturing excellence and deep customer collaboration to create sustainable value for our stakeholders. As we look ahead, we remain encouraged by the improving visibility across our businesses. The normalization in our PI Intermediate business, continued momentum in contrast media, execution of our strategic expansion projects and strengthening product pipeline, collectively reinforce our confidence in the company's medium and long-term growth trajectory. To conclude, we believe this quarter represents more than an improvement in operating performance. It reflects the early outcome of investments we have been making over the several years. and strengthens our confidence in Blue Jet's long-term growth strategy. Thank you once again for your continued trust and confidence in Blue Jet Healthcare. I now invite Mr. V.K. Singh to take you through the operational and product development updates following with our CFO, Mr. Ganesh, who will discuss the financial performance in greater detail. Thank you. VK Singh: Thank you, Shiven, and good evening, everyone. As Shiven mentioned at the outset, we have started FY27 with a very encouraging quarter, reinforcing the momentum that we are building across our product verticals. However, our focus continues to remain well beyond quarterly performance. Our objective is to build a globally competitive innovation-led CDMO platform capable of supporting customers from development through commercial manufacturing cycle. This journey Page 3 of 16 Blue Jet Healthcare Limited August 03, 2026 is anchored on 2 strategic pillars: globally competitive manufacturing infrastructure and differentiated R&D capabilities. At Unit 3, as Shiven briefly mentioned, Mahad, we are establishing a globally scaled manufacturing facility for strategically important contrast media intermediates. Once commissioned later this calendar year and here, I must emphasize that earlier, we had guided H2, but I think we are slightly ahead of schedule here. This project will position Blue Jet a [Showing first 8,000 characters — download PDF for full document]